secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2024-06-10T23:59:59+00:00
Accession:  0001213900-24-051355
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Oramed Pharmaceuticals appoints Avraham Gabay as CFO effective June 18, 2024
----------------------------------------------------------------------------

- Avraham Gabay appointed CFO, Treasurer, and Secretary, effective June 18, 2024.
- Gabay previously served as interim CFO of BiomX Inc. (NYSE American: PHGE) since 2023.
- He served as CFO of Oramed from 2019-2021 and as CFO of its 63% subsidiary Oravax Inc. from 2021-2023.
- Compensation: gross monthly salary NIS 68,000, company car, eligibility for bonuses and equity at board discretion.
- Gabay holds law and accounting degree from Tel-Aviv University, is a CPA in Israel and member of Israeli Bar.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024051355/0001213900-24-051355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024051355/ea0207486-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-051355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer